Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).

被引：4
|
作者：
Munster, Pamela N.
Hamilton, Erika Paige
Franklin, Catherine
Bhansali, Suraj
Wan, Kitty
Hewes, Becker
Juric, Dejan
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] Novartis Inst Biomed Res, Cambridge, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [42] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [43] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [44] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [45] A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
    Vaklavas, Christos
    Stringer-Reasor, Erica M.
    Elkhanany, Ahmed M.
    Ryan, Kevin J.
    Li, Yufeng
    Theuer, Charles P.
    Acosta, Edward P.
    Wei, Shi
    Yang, Eddy S. S.
    Grizzle, William E.
    Forero-Torres, Andres
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (02) : 217 - 229
  • [46] Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC)
    Collier, Ann
    Mac Gregor, Mariana Chavez
    Hilz, Stephanie
    Bardia, Aditya
    Sohn, Joohyuk
    Martin, Miguel
    Lim, Elgene
    Martinalbo, Jorge
    Perez-Moreno, Pablo Diego
    Moore, Heather M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)
    Yuan, Y.
    Mortimer, J.
    Xing, Q.
    Yan, J.
    Wen, W.
    Han, E.
    Yim, J. H.
    CANCER RESEARCH, 2017, 77
  • [48] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Hamilton, Erika P.
    Pluard, Timothy J.
    Wang, Judy S.
    Morikawa, Aki
    Johnston, Stephen R. D.
    Dees, Elizabeth Claire
    Vaklavas, Christos
    Armstrong, Anne C.
    Munster, Pamela N.
    Unni, Nisha
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
    Christos Vaklavas
    Erica M. Stringer-Reasor
    Ahmed M. Elkhanany
    Kevin J. Ryan
    Yufeng Li
    Charles P. Theuer
    Edward P. Acosta
    Shi Wei
    Eddy S. Yang
    William E. Grizzle
    Andres Forero-Torres
    Breast Cancer Research and Treatment, 2023, 198 : 217 - 229
  • [50] A phase lb study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer
    Baselga, Jose
    Curigliano, Giuseppe
    Martin, Miguel
    Andre, Fabrice
    Beck, J. Thaddeus
    Tortora, Giampaolo
    Wilke, Celine
    Charbonnier, Laure
    Blumenstein, Lars
    Donnet, Valerie
    Fazio, Nicola
    CANCER RESEARCH, 2016, 76
12345